Matthieu Allez
Experienced in Collagenous Colitis

Matthieu Allez

Paris, FR 
Experienced in Collagenous Colitis
Paris, FR 
OverviewLocationsClinical Research

Overview

Matthieu Allez practices in Paris, France. Mr. Allez is rated as an Experienced expert by MediFind in the treatment of Collagenous Colitis. His top areas of expertise are Crohn's Disease, Viral Gastroenteritis, Colitis, Ileostomy, and Colonoscopy.

His clinical research consists of co-authoring 191 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Collagenous Colitis.

Gender
Male

Locations

Paris, France
Other Locations
1 Avenue Claude, Vellefaux, 75010, France
Clichy-sous-bois, France
Port-saint-louis-du-rhone, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical Trial
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical Trial
Enrollment Status: Completed
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drugs: Infliximab, Vedolizumab Injection
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn's Disease Who Have Participated in ADMIRE II Study
A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn's Disease Who Have Participated in ADMIRE II Study
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Biological, Other
Study Drug: Darvadstrocel Adipose Stem Cell Transplantation
Study Phase: Phase 3
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2024
Intervention Type: Drug
Study Drug: Ustekinumab
Study Phase: Phase 4
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
Enrollment Status: Terminated
Publish Date: September 07, 2023
Intervention Type: Drug
Study Drug: TAK-018
Study Phase: Phase 2
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drugs: Azathioprine, Infliximab, Prednisolone, Hydrocortisone
Study Phase: Phase 4
Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis
Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis
Enrollment Status: Completed
Publish Date: July 31, 2018
Intervention Type: Procedure
Study Phase: Not Applicable
Evaluation of the Diagnostic Value of microRNAs for Inflammatory Bowel Disease
Evaluation of the Diagnostic Value of microRNAs for Inflammatory Bowel Disease
Enrollment Status: Completed
Publish Date: May 21, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 10 Less Clinical Trials

191 Total Publications

Blood proteomic signatures associated with disease activity in Inflammatory Bowel Diseases.
Blood proteomic signatures associated with disease activity in Inflammatory Bowel Diseases.
Journal: Journal of Crohn's & colitis
Published: September 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Allez's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile